Abstract: In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.

Abstract: In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.

Abstract: Devices, systems, and methods for regulating glucose levels, including treating diabetes, in accordance with the present disclosure may include a catheter having an expandable or inflatable portion, one or more electrodes disposed on the expandable or inflatable portion of the catheter, wherein the electrodes are configured to deliver energy to a patient's gastrointestinal tract, and a drug delivery mechanism for delivering a drug therapy subsequent to energy delivery by the electrodes. A method for regulating glucose levels according to the present disclosure may include inserting a catheter into a patient's gastrointestinal tract, positioning the catheter in a duodenum of the patient's gastrointestinal tract, expanding or inflating a portion of the catheter in the duodenum, the expandable or inflatable portion of the catheter including electrodes, applying energy to the duodenum via the electrodes to ablate tissue of the duodenum, and delivering a drug therapy to the ablated tissue of the duodenum.

Abstract: In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.

Abstract: A system and method for isolating and separating lipoaspirate particles. The system includes a generally cylindrical container having a lid and a bottom wherein the container includes at least one input port positioned to permit a lipoaspirate fluid to enter the container above the bottom; and a source of a vacuum coupled to the container to provide a partial vacuum during use of the system.

Abstract: A system and method for isolating and separating lipoaspirate particles. The system includes a generally cylindrical container having a lid and a bottom wherein the container includes at least one input port positioned to permit a lipoaspirate fluid to enter the container above the bottom; and a source of a vacuum coupled to the container to provide a partial vacuum during use of the system.